Denali Therapeutics Inc DNLI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
-
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
-
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
-
Takeda Ends Denali Therapeutics Dementia-Drug Partnership
-
Denali Therapeutics' Hunter Syndrome Drug Review Extended by FDA
Trading Information
- Previous Close Price
- $18.66
- Day Range
- $18.01–18.50
- 52-Week Range
- $13.75–27.30
- Bid/Ask
- $18.51 / $19.50
- Shares Outstanding
- 159.85M
- Market Cap
- $2.94B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 921.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 507
Valuation
|
Metric
|
DNLI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.52 |
Price/Sales | 921.88 |
Price/Cash Flow | — |
Price/Earnings
DNLI
Financial Strength
|
Metric
|
DNLI
|
|---|---|
Quick Ratio | 7.93 |
Current Ratio | 8.37 |
Interest Coverage | — |
Quick Ratio
DNLI
Profitability
|
Metric
|
DNLI
|
|---|---|
Return on Assets (Normalized) | −35.95% |
Return on Equity (Normalized) | −44.03% |
Return on Invested Capital (Normalized) | −45.47% |
Return on Assets
DNLI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<VP<@v | LOCK|wf%jN | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?lxXN> | LOCK|SY$H? | $83B | |||
| Moderna Inc
MRNA
| LOCK|tt?ZyJ | LOCK|@x> | $80B | |||
| argenx SE ADR
ARGX
| LOCK|<$@M#g | LOCK|%P | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|q<H@VGV | LOCK|Z% | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|z&JjqW | LOCK|Skf!J | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|CqLnJxJj | LOCK|Nbjv | $28B | |||
| Incyte Corp
INCY
| LOCK|>TZ$c^% | LOCK|C@@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|kZ^VZG | LOCK|k! | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>Hgy#v$ | LOCK|zm | $14B |
United States